Inhalation products developed by Skyepharma

Skyepharma has successfully developed a number of inhalation products in collaboration with its multinational partners, resulting in approvals in over 30 countries worldwide, including the US.  These development programmes have incorporated our proprietary formulation and device technologies, and include Dry Powder Inhaler (DPI) and Metered-Dose Inhaler (MDI) products. The successful development of  flutiform® pMDI which is approved and marketed in Europe and Japan is the most recent example.

Skyepharma has also licensed some of its proprietary formulation technologies to facilitate developments by major pharmaceutical companies, such as GlaxoSmithKline.

> Find out more about our inhalation development pipeline

Contact us to find out how we can help you advance your inhalation product development project.

Flutiform which was developed by Skyepharma from original concept to regulatory approval

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens
London
SW1W 0EB
UK

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz
Switzerland

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.